Apexion Health Estradiol topical cream
HORMONEWOMEN'S HEALTH

MONTHLY SUPPLY · TOPICAL CREAM

ESTRADIOL

TREATMENT

Bioidentical estrogen for women's hormone balance

SUPPORT

Bioidentical estradiol cream delivers 17β-estradiol — chemically identical to endogenous estrogen — transdermally for perimenopause and menopause symptom relief, bone protection, and cardiovascular support.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — HORMONE

BIOIDENTICAL ESTROGEN. BALANCED BY DESIGN.

Estradiol (17β-estradiol) is the primary estrogen produced by the ovaries during reproductive years. As ovarian function declines in perimenopause and menopause, estradiol levels fall — producing hot flashes, night sweats, vaginal dryness, mood changes, sleep disruption, and accelerated bone loss. Transdermal bioidentical estradiol cream restores physiological estrogen levels through the skin, bypassing first-pass hepatic metabolism and delivering a more stable serum profile than oral synthetic formulations.

Clinical Benefits

ESTRADIOL SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    REDUCES HOT FLASHES AND VASOMOTOR SYMPTOMS

  2. 02.

    SUPPORTS VAGINAL TISSUE HEALTH AND MOISTURE

  3. 03.

    PROTECTS AGAINST ESTROGEN-DEFICIENCY BONE LOSS

  4. 04.

    IMPROVES SLEEP QUALITY AND MOOD STABILITY

  5. 05.

    TRANSDERMAL DELIVERY BYPASSES HEPATIC FIRST PASS

  6. 06.

    PHYSICIAN-MONITORED BIOIDENTICAL FORMULATION

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

Menopausal Symptom Relief

Vaginal Atrophy Improved maturation index80%
Hip Fracture Risk HR 0.66 (WHI) — 34% reduction34%
Hot Flash Frequency ~75% reduction from baseline75%

WHI Estrogen-Alone, JAMA 2004; ELITE Trial, NEJM 2016

02 — Hormone Panel

Clinical Outcomes with Systemic ET

MarkerWithoutWith Treatment
Hot Flash Freq./day
7.5
1.9−75%
Hip Fracture RiskHR
1.0
0.66−34%
Vaginal pHpH
6.2
4.5−1.7
Vaginal Mat. Index% sup
5
45+40

Timing hypothesis — start within 6 years of menopause

ELITE trial (Hodis 2016): estrogen started <6 yrs post-menopause may have CV benefit; >10 yrs may be neutral/harmful. Transdermal preferred for lower VTE risk.

WHI JAMA 2004; ELITE NEJM 2016; NAMS 2022 Position Statement

03 — Protocol

Systemic HRT Initiation

BaselinePre-treatment
  • ›Symptom severity score
  • ›Lipid panel, LFTs
  • ›Mammogram (if due)
  • ›Endometrial assessment if uterus
InitiationMonths 1–3
  • ›Low-dose E2 (transdermal preferred)
  • ›Symptom diary
  • ›Tolerability & bleeding pattern
Long-termMonth 4+
  • ›Symptom reassessment q6–12 months
  • ›Annual mammogram
  • ›Endometrial monitoring
  • ›Annual risk/benefit review

MUST add progestogen if uterus present

Unopposed estrogen: 20–30% annual hyperplasia risk. Add micronized progesterone 100–200 mg/day. Transdermal E2 (<50 mcg/day) has lower VTE risk. Lowest effective dose, shortest duration.

All protocols physician-supervised and adjusted per individual labs.